Agent Capital
Description
Agent Capital is a Cambridge, Massachusetts-based venture capital firm specializing in the life sciences sector. Founded by experienced professionals in biotech and finance, the firm is dedicated to investing in and building companies that develop novel therapeutics, innovative platform technologies, and medical devices. Their strategic location in a major biotech hub allows them close proximity to cutting-edge research and talent, fostering a collaborative environment for their portfolio companies.
The firm's investment strategy spans various stages, from seed and early-stage ventures to growth equity opportunities. Agent Capital seeks to identify and support companies with strong scientific foundations, addressing significant unmet medical needs. They often take an active role in their portfolio companies, leveraging their deep industry expertise and extensive network to accelerate development and commercialization, aiming to translate scientific breakthroughs into tangible patient benefits.
Agent Capital has demonstrated significant fundraising success, underscoring investor confidence in their approach. They successfully closed their debut fund, Agent Capital Fund I, L.P., in 2020 with $150 million in commitments. Building on this momentum, the firm announced the closing of Agent Capital Fund II, L.P. in 2023, which secured $300 million. These substantial funds enable Agent Capital to make meaningful investments and provide sustained support to their portfolio companies throughout their growth trajectories.
Their portfolio reflects a diverse range of therapeutic areas, including oncology, immunology, neurology, and rare diseases, among others. Agent Capital's commitment extends beyond capital, offering strategic guidance and operational support to help transformative life science companies bring their innovations to patients and make a lasting impact on global health.
Investor Profile
Agent Capital has backed more than 49 startups, with 4 new investments in the last 12 months alone. The firm has led 4 rounds, about 8% of its total and boasts 10 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States, United Kingdom, France.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
- Typical check size: $5M – $25M.
Stage Focus
- Series B (41%)
- Series A (24%)
- Series C (14%)
- Series Unknown (10%)
- Seed (6%)
- Post Ipo Equity (2%)
- Series D (2%)
Country Focus
- United States (90%)
- United Kingdom (4%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- France (4%)
- Switzerland (2%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Life Science
- Biopharma
- Pharmaceutical
- Genetics
- Health Diagnostics
- Machine Learning
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
